Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer
8.7.2024 09:00:00 EEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
Contacts
Communications advisor to Epsilogen Ltd:
Simon Conway
Senior Managing Director
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Enters Collaboration Agreement with Solutia26.3.2026 17:59:00 EET | Press release
Andersen Consulting expands its presence in Spain through a Collaboration Agreement with Solutia, a firm specializing in occupational and workplace health solutions, as well as recruitment across the life sciences and healthcare sectors. Founded in 2014, Solutia provides comprehensive services and consulting focused on healthy work environments, absenteeism, healthcare outsourcing, and training for organizations across all sectors. The firm also delivers recruitment and executive search solutions specialized in life sciences, technical professionals, and middle and executive management, with deep expertise in the pharmaceutical, biotechnology, medical technology, and healthcare industries. Solutia helps organizations enhance workforce efficiency and attract specialized talent through tailored solutions based on data. “We are committed to advancing how organizations attract, develop, and manage talent in an increasingly complex environment,” said Cesar Castel, managing director of Solut
CSG Named a Leader in the Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration26.3.2026 17:30:00 EET | Press release
Rising customer expectations for connected, relevant, and effortless interactions are making journey analytics and orchestration critical to delivering consistent, personalized experiences that earn loyalty. As CSG® (NASDAQ: CSGS) helps businesses to meet and exceed those expectations, the company today announced that CSG has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Customer Journey Analytics & Orchestration. The evaluation assessed the company’s overall Completeness of Vision and Ability to Execute. “It’s not enough to understand the customer – businesses must act on that knowledge in real time and prove the value of every customer interaction,” said Katie Costanzo, President, Customer Experience, CSG. “That requires a unified system that turns real-time data into clear decisions, measurable outcomes, and experiences customers can trust. I am incredibly proud that CSG has been named a Leader in the inaugural Gartner Magic Quadrant for Journey Analytics & Orchestrat
India: The Up-and-Coming Solar Market26.3.2026 17:27:00 EET | Press release
Solar energy expansion is booming worldwide. India, in particular, is seeing rapid growth thanks to state funding programs, tax incentives, subsidies and green loans from banks. In 2025, 37.5 gigawatts were added – a 50 percent increase from the previous year. The 2026 budget provides for a deployment of 45 to 50 gigawatts, allowing the most densely populated country to become the second largest solar market in the world. Intersolar Europe will shine a spotlight on the south Asian country from June 23–25 in Munich. India is an up-and-coming market for the international PV industry. There will be numerous events where visitors can learn about the market, new business opportunities and the structure of new supply chains. The exhibition will take place as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry. More than 100,000 visitors and 2,800 exhibitors from all over the world are expected to attend. This press release features multimedia. View
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom